MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in the following upcoming investor conference:
Related news for (MGNX)
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/10/25 07:00 AM
- MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
- MacroGenics Receives $70M from Sagard Healthcare Partners in Royalty Agreement for ZYNYZ
- 24/7 Market News Snapshot 10 June, 2025 – MacroGenics, Inc. (NASDAQ:MGNX)
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/06/25 12:00 PM